Atyr PHARMA INC (NASDAQ:ATYR) Director Jane A. Gross Buys 3,750 Shares

Atyr PHARMA INC (NASDAQ:ATYR) Director Jane A. Gross acquired 3,750 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $4.00 per share, with a total value of $15,000.00. Following the completion of the acquisition, the director now owns 9,750 shares in the company, valued at approximately $39,000. The trade was a 62.50 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Atyr PHARMA Stock Up 1.0 %

ATYR stock traded up $0.04 during trading on Monday, reaching $4.01. The stock had a trading volume of 2,054,474 shares, compared to its average volume of 826,408. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $3.65 and a 200 day moving average price of $3.09. The company has a market capitalization of $336.61 million, a P/E ratio of -4.27 and a beta of 0.98. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, equities analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Institutional Trading of Atyr PHARMA

Hedge funds have recently made changes to their positions in the stock. D.A. Davidson & CO. acquired a new position in shares of Atyr PHARMA in the 4th quarter worth approximately $141,000. JPMorgan Chase & Co. grew its position in shares of Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after acquiring an additional 10,754 shares during the last quarter. Alterna Wealth Management Inc. acquired a new stake in shares of Atyr PHARMA in the 4th quarter worth about $36,000. Kingswood Wealth Advisors LLC bought a new stake in Atyr PHARMA in the 4th quarter valued at about $170,000. Finally, American Century Companies Inc. acquired a new position in Atyr PHARMA during the 4th quarter valued at about $319,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Leerink Partners assumed coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.